What one share of Tenax Therapeutics holds
Tenax Therapeutics is a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies. We employ a clinician-driven drug development approach, led by key opinion leaders and heart failure experts and informed by their clinical insights to precisely target disease pathophysiology.
Tenax Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$1.47 |
| Cash and investments | $3.69 |
| Book value | $3.56 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | — | −$31.04 | — | — | — | $27.15 |
| 2024 | $0.00 | −$1.15 | — | — | — | — |
| 2025 | $0.00 | −$1.34 | — | — | — | $10.42 |
Common questions about Tenax Therapeutics
How much does one share of Tenax Therapeutics earn?
Over the last 12 months, Tenax Therapeutics lost $1.47 for each share.
Does Tenax Therapeutics pay a dividend?
Tenax Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Tenax Therapeutics’s book value per share?
Tenax Therapeutics’s book value is $3.56 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Tenax Therapeutics have?
Each share of Tenax Therapeutics has $3.69 of cash and investments, as of June 30, 2026.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.